Latest Conference Articles

Glenn Tillotson, PhD, highlights possible treatment options besides antibiotics that may be worth evaluating for the infectious disease.

Data from a new study indicate that trauma is an independent risk factor for cardiovascular disease in sexual minority women, suggesting it should be screened for as a risk factor in this population.

Dale Gerding, MD, highlights newest and most promising treatment approaches and preventions for C difficile.

Catia Mato Ferreira, PhD, global medical lead of Medical Affairs at Pfizer discussed the preventive potential of the C difficile vaccine that is currently in development in a phase 3 trial.

Nicola Petrosillo, MD, discusses current controversies in C difficile prevention and treatment.

Investigators have found an association between opioid use and cardiovascular mortality.

Combining glaucoma medications into a single eye drop could simplify regimens and reduce costs for patients. Investigators found that a combination eye drop also significantly reduced intraocular pressure compared to control.

New data shows patients with rheumatoid arthritis do not change their current treatment to reach a “treat-to-target” goal for low disease activity.

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

Authors compared investigator assessments to reading center-assessed optical coherence tomography outcomes to evaluate intravitreal aflibercept injection with or without rescue photodynamic therapy.

Patients with severe scleroderma who were treated with hematopoietic stem cell transplantation showed significant improvement in long-term outcomes such as survival and functional status.

A new study emphasizes the need for specially designed syringes that ensure accuracy and precision when administering anti-VEGF agents via intravitreal injection.

Ronald Gentile, MD, and colleagues investigated pain-reduction strategies following intravitreal injections. The results have implications for patient experience, physician ratings, and treatment adherence.

R. Theodore Smith, MD, PhD, discusses the importance of developing non-invasive technologies that can detect age-related macular degeneration earlier.

A new phase 3 study suggests that physicians should shift away from periocular injections, and towards intravitreal injections of corticosteroids for uveitic macular edema.

While it is critical to recognize diabetic macular edema patients with delayed treatment response to reduce the progression of vision loss, improve quality of life, this may come at a cost to the institution.

After analyzing 57,925 injections administered 2013 and 2017, investigators observed an increase in aflibercept use, with a reciprocal decline in ranibizumab across all regions, while the use of bevacizumab remained stable.

Patients treated with faricimab every 16 weeks had a mean improvement of 11.4 letters from baseline, compared to 9.6 letters in those treated with ranibizumab every 4 weeks.

The phase 2 FILLY trial found that APL-2 injections both monthly and every other month slowed lesion growth compared to sham.

The data presented at the American Academy of Ophthalmology indicates dosing IAI with treat and extend resulted in more visual acuity gains when compared to fixed dosing.

R. Theodore Smith MD, PhD, discusses the concept of hyperspectral autofluorescence imaging and how clinicians can learn more from this method than standard autofluorescence imaging.

According to an analysis of 84,228 online reviews of 7,372 ophthalmologists, the average rating for a physician with a wait time exceeding 15 minutes was 3.903.

In a new study conducted in Taiwan, investigators found that use of metformin to treat diabetes also reduced the risk of AMD development over a 13-year period.

In patients with neovascular AMD, 24% receiving brolucizumab had intra-retinal fluid and/or sub-retinal fluid compared to 37% of aflibercept-treated patients in the HAWK trial.

Peter Campochiaro, MD, professor of ophthalmology and director of the retinal cell and molecular laboratory at Johns Hopkins explains the burdens of receiving frequent anti-VEGF injection treatments.

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months was 1.3 in a phase 1 cohort study.

R. Theodore Smith MD, PhD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai discusses new research to reduce the burden of AMD and how imaging can revolutionize the retina space.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

In a phase 1 trial, patients in the femto-assisted crosslinking treatment arm had a more favorable outcome in the retention of corneal thickness, when compared to the conventional therapy group.